Cancer reports最新文献

{"title":"Computational Design of an mRNA Vaccine Targeting LRP6 for Triple-Negative Breast Cancer Therapy.","authors":"Pooriya Teimoori, Mohammadreza Heidari","doi":"10.1002/cnr2.70567","DOIUrl":"https://doi.org/10.1002/cnr2.70567","url":null,"abstract":"<p><strong>Background: </strong>Triple-negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options. TNBC exhibits increased levels of LRP6 expression, which is linked to tumor-related features such as growth, metastasis, poor prognosis, resistance to chemotherapy, and invasion. Therefore, LRP6 offers a promising option for therapeutic intervention in breast cancer.</p><p><strong>Aims: </strong>This research aims to use in silico and bioinformatics techniques to develop an mRNA vaccine that specifically targets the LRP6 antigen.</p><p><strong>Methods and results: </strong>The final vaccine construct comprised 431 amino acids, with a molecular weight of 47.5 kDa, theoretical pI of 5.11, and an instability index of 38.3 indicating stability. Population coverage analysis showed broad global coverage of 99.04%. Molecular docking revealed strong binding affinities to immune receptors, including HLA-A0201 (-812.0), HLA-A0301 (-707.1), HLA-DRB1*0101 (-955.7), and TLR9 (-1339.5). Immune simulation predicted high titers of IgG1 antibodies, sustained memory B cell populations (> 200 by Day 365), elevated CD4+ T cells (> 3000), and robust IFN-γ responses. Codon optimization yielded a high CAI value of 0.94 and GC content of 58.37%, supporting efficient expression in human systems.</p><p><strong>Conclusion: </strong>Collectively, these results suggest that the designed LRP6-targeted mRNA vaccine could induce durable humoral and cellular immunity against TNBC and warrants further experimental validation.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70567"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143567/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observation on the Efficacy of Hyperbaric Oxygen as Adjuvant Therapy for Breast Cancer-Related Wounds: A Case Report.","authors":"Fengrong Tang, Lei Zhang, Shufang Lu, Xiaochen Mo, Xiaoxiao Duan","doi":"10.1002/cnr2.70563","DOIUrl":"10.1002/cnr2.70563","url":null,"abstract":"<p><strong>Background: </strong>Hyperbaric oxygen therapy (HBOT) is widely used as a therapeutic intervention for various types of wounds. Studies have shown that in addition to improving local oxygen supply to the wound site, HBOT can also influence cytokine activity, promote the survival of tissue mesh, and thereby facilitate wound healing. Moreover, HBOT inhibits the growth and reproduction of various pathogenic bacteria and enhances the phagocytic capacity of leukocytes, effectively preventing and controlling infection.</p><p><strong>Case: </strong>This case study involves a 61-year-old female diagnosed with invasive micropapillary carcinoma, who underwent a combination of treatments including radiotherapy, chemotherapy, immunotherapy, and targeted therapy. Nine years post-surgery, the patient experienced a recurrence of left breast cancer, accompanied by cancer wounds with exudate, edema, and ulceration in multiple areas such as the chest and back. Following comprehensive treatment consisting of anti-infective therapy, nutritional support, and edema management, along with three courses of adjuvant HBOT, the patient showed significant improvement in wound exudate and odor, resolution of lymphedema, and a reduction in wound volume, although the wound area did not show notable change.</p><p><strong>Conclusion: </strong>This study implemented a comprehensive care plan for patients with malignant wounds, including measures such as wound debridement, anti-infection treatment, nutritional support, and HBOT. Following the integrated intervention, symptoms including wound exudate, odor, and lymphedema were alleviated, and wound volume was reduced, although no significant change was observed in wound area. The primary benefit of HBOT in malignant wound management lies in symptom control, while its effect on structural wound healing appears limited. Its specific role within multidisciplinary comprehensive care requires further investigation.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70563"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13128304/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147762725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells.","authors":"Natalie Aderhold, Lisa Immesberger, Sabine Becker, Till Milde, Bernd Gruhn, Jürgen Sonnemann","doi":"10.1002/cnr2.70568","DOIUrl":"https://doi.org/10.1002/cnr2.70568","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma is the most common bone cancer in children and young adults. Its prognosis has not improved significantly since the introduction of the chemotherapy regimen established about 40 years ago, highlighting the need for new therapeutic strategies.</p><p><strong>Aims: </strong>The present study was undertaken to assess the effectiveness of combined inhibition of two promising drug targets, ATR and ribonucleotide reductase (RNR), in osteosarcoma cells.</p><p><strong>Methods and results: </strong>The ATR inhibitor berzosertib and the RNR inhibitors triapine and didox were tested in TP53 wild-type (U2OS, MG-63) and mutant (SaOS-2) osteosarcoma cell lines. Combination effects were examined by flow cytometric analysis of cell death, loss of the mitochondrial membrane potential and DNA fragmentation as well as by caspase 3/7 activity assay and real-time RT-PCR. The drug interactions were evaluated using combination index analysis. Single treatment with ATR or RNR inhibitors resulted in mild to moderate effects, whereas combined treatment resulted in strong and synergistic effects. ATR and RNR inhibitors cooperated to elicit loss of the mitochondrial membrane potential, to activate caspase 3/7 and to trigger DNA fragmentation, suggesting that the combination of ATR and RNR inhibitors induced an apoptotic form of cell death. The cytotoxic effects were independent of TP53 mutational status.</p><p><strong>Conclusion: </strong>Our study demonstrates that combined inhibition of ATR and RNR was effective in osteosarcoma cells. These in vitro findings offer support for investigating in vivo the potential of a combination of ATR and RNR inhibitors as a new treatment strategy for osteosarcoma.</p>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 5","pages":"e70568"},"PeriodicalIF":1.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13143566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bacterial Infections Role in Gynecological Cancers Development: Narrative Review","authors":"Robab Azargun,&nbsp;Maryam Azargoon,&nbsp;Zahra Asefy,&nbsp;Mina Yekani,&nbsp;Vahideh Tarhriz,&nbsp;Fatemeh Yeganeh,&nbsp;Mohammad Yousef Memar,&nbsp;Shirin Eyvazi","doi":"10.1002/cnr2.70499","DOIUrl":"https://doi.org/10.1002/cnr2.70499","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Gynecological cancers are among the most common cancers in women that affect female reproductive organs. The most common gynecological cancers are ovarian, cervical, uterine/endometrial, vaginal, and vulvar cancer. Women's reproductive organs have a dynamic and relative microbial balance. The disruption in the balance of the microbiome could result in numerous gynecological diseases, as well as, gynecological cancers. In this study, we aimed to review new findings on the role of different bacterial infections in various types of gynecological cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>The role of bacterial infection, as an external factor, has been established in several cancers. However, the ways in which bacteria can promote the development of cancer are not fully understood. It seems that inflammation induced by bacterial infections could promote carcinogenesis. In addition, bacterial toxins and effector proteins play important roles in the progression of cancer. In this review, we attempt to present the different bacterial infections, which have been linked to gynecological cancers development. According to different researches, <i>Chlamydia</i>, <i>Mycoplasma</i>, and <i>Bacteroides</i> spp. are the most common bacterial infections associated with gynecological cancers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Evaluation of microbiome in reproductive organs of the patients with gynecological cancer and studies on prevention and control of the infections in the patients could be useful in verification of pathogenesis of the diseases and also founding suitable therapeutic interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70499","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147668520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete Response to Nivolumab-Relatlimab Following Progression of Invasive Sinonasal Mucosal Melanoma on First-Line Nivolumab-Ipilimumab: A Case Report","authors":"Reema Patel,&nbsp;Louisa Post-Zwicker,&nbsp;Varinder Kaur","doi":"10.1002/cnr2.70544","DOIUrl":"10.1002/cnr2.70544","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma with a notably worse prognosis than cutaneous melanoma (CM) due to its occult presentation and unique molecular profile. For advanced cases, immunotherapy has improved outcomes in recent years, although more significantly for CM. The recently approved combination of nivolumab and relatlimab has emerged as a promising option for advanced melanoma and a potential alternative to the well-established nivolumab-ipilimumab regimen. Due to the rarity of MM often limiting thorough evaluation in trials, there remains a lack of guidance regarding the most appropriate regimen for optimal patient outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case</h3>\u0000 \u0000 <p>A 70-year-old male with T4aN0M0 sinonasal MM was initiated on neoadjuvant nivolumab-ipilimumab therapy; however, disease progression soon after rendered the tumor unresectable. Despite undergoing 4 cycles, metastatic progression ensued, necessitating a shift to nivolumab-relatlimab therapy. Following 8 cycles of nivolumab-relatlimab alongside radiation to metastatic sites, the patient achieved a complete response, with no signs of active disease. Unfortunately, during a seven-week treatment interruption due to suspected immune-related gastrointestinal toxicity requiring corticosteroids, routine PET-CT monitoring revealed findings suspicious for new metastasis. Despite one additional cycle of immunotherapy, the patient's functional status deteriorated. Although repeat imaging showed stable disease, the patient elected to transition to supportive care without further treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case exemplifies the use of nivolumab-relatlimab in achieving a complete response in a patient with advanced sinonasal MM that progressed after nivolumab-ipilimumab. While further investigation is needed to clarify the comparative efficacy of existing combination immunotherapy options, this report highlights nivolumab-relatlimab as a promising option with a potentially favorable safety profile in this rare and aggressive melanoma subtype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70544","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor-Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis","authors":"Taira Hada,&nbsp;Morikazu Miyamoto,&nbsp;Takahiro Einama,&nbsp;Soichiro Kakimoto,&nbsp;Makiko Koga,&nbsp;Takanori Watanabe,&nbsp;Yuka Otsuka,&nbsp;Jin Suminokura,&nbsp;Tsubasa Ito,&nbsp;Naohisa Kishimoto,&nbsp;Risa Tanabe,&nbsp;Soko Nishimura,&nbsp;Kento Kato,&nbsp;Hiroaki Soyama,&nbsp;Kohei Omatsu,&nbsp;Yoshinobu Hamada,&nbsp;Kimiya Sato,&nbsp;Masashi Takano","doi":"10.1002/cnr2.70535","DOIUrl":"10.1002/cnr2.70535","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor-infiltrating lymphocytes (TILs) based on artificial intelligence (AI).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin-stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm²) in the annotated area was calculated using AI. Patients were classified into the High-TIL and Low-TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)-related proteins were evaluated using immunohistochemical staining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 659 patients were included: 346 (52.5%) in the High-TIL group and 313 (47.5%) in the Low-TIL group. MMR deficiency was observed more frequently in the High-TIL group than in the Low-TIL group (<i>p</i> &lt; 0.01). Progression-free survival (PFS) and overall survival (OS) were better in the High-TIL group than in the Low-TIL group (both <i>p</i> &lt; 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); <i>p</i> &lt; 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); <i>p</i> = 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13066499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147643509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis","authors":"Desta Seyoum Tadesse,&nbsp;Kalkidan Tekletsadik,&nbsp;Berhan Begashaw,&nbsp;Awgichew Shewasinad Yehualashet,&nbsp;Awol Mekonnen Ali,&nbsp;Kassahun Dires Ayenew","doi":"10.1002/cnr2.70538","DOIUrl":"10.1002/cnr2.70538","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pharmacovigilance has revealed an alarming correlation between certain medications and a higher risk of cancer. In this narrative review, included research from 2020 to 2025, along with a few seminal older studies, so that it provides a clear picture of which drugs actually set off cancer and mechanisms involved at the molecular level. An extensive literature review of the subject was designed on PubMed, Embase, Scopus, and Web of Science using systematic search. Search words and phrases included: “Carcinogenic drugs,” “drug-induced cancer,” “medication-induced carcinogenesis,” “immunosuppressant cancer risk,” “hormone therapy and cancer,” “chemotherapy-induced secondary malignancies,” and names of relevant drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Our discussion covers a broad spectrum of drugs, including immunosuppressants, hormone therapies, and chemotherapy agents that can unsurprisingly cause secondary cancers. The review has addressed that there are other medications with solid evidence linking them to cancer. The review focuses on how cancers are induced by chemicals through DNA damage, epigenetic modifications, chronic inflammation, immunological suppression, and receptor-mediated signaling pathways.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A thorough understanding of the risk and mechanisms is essential for the design of safer therapies, implementation of risk reduction strategies, and advancement of informed prescribing practice.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiproliferative Effect of 24-Deoxysericoside From Terminalia macroptera Guill. & Perr. (Combretaceae) Against Breast Carcinoma: In Vitro, Molecular Docking and ADME Assessment","authors":"Romeo Toko Feunaing,&nbsp;Alfred Ngenge Tamfu,&nbsp;Abel Joel Yaya Gbaweng,&nbsp;Cyrille Leonel Tchuente Djoko,&nbsp;Emmanuel Talla,&nbsp;El Hassane Anouar,&nbsp;Stephane Zingue","doi":"10.1002/cnr2.70541","DOIUrl":"10.1002/cnr2.70541","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Terminalia macroptera</i> (Combretaceae) is an important medicinal plant in the traditional pharmacopeia in most tropical areas, where its different parts are used in treating illnesses including cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>In this study, two oleanane-type triterpenoids: terminolic acid (TM32) and arjungenin (TM34), together with three saponins: arjunglucoside I (TM35), 24-deoxysericoside (TM36) and chebuloside II (TM37) from <i>T. macroptera</i>, were screened for their cytotoxic effects against breast cancer cell lines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>The compounds were isolated using column chromatography and characterized from their NMR data. Their cytotoxic and antiproliferative effects against estrogen non-sensitive (MDA-MB 231) and estrogen sensitive (MCF-7) breast cancer cell lines were evaluated. Against estrogen non-sensitive (MDA-MB 231) cancer cell lines, deoxysericoside (TM36) was profoundly active compared to the control. Terminolic acid (TM32), arjungenin (TM34), and arjunglucoside I (TM35) were also active. Against estrogen sensitive (MCF-7) breast cancer cell lines, deoxysericoside (TM36) exhibited significant activity (<i>p</i> &lt; 0.05) compared to control experiments. The most active compound had an optimum concentration of 30 μg/mL. Deoxysericoside (TM36) showed concentration-dependent inhibition percentages at 15 and 30 μg/mL, and MDA-MB 231 breast carcinoma cells were more susceptible. MDA-MB 231 treated with 15 and 30 μg/mL of deoxysericoside (TM36) showed significant reduction (<i>p</i> &lt; 0.05) in clone formation after 48 h when compared to untreated controls, suggesting that it can restrict cancer to a preliminary stage. The deoxysericoside (TM36) reduced cell migration with dose-dependent improvement in wound healing at 15 and 30 μg/mL, revealed by the micrographs. Molecular docking indicated that the compounds fit well into hERα and PI3Kα receptor binding sites, forming stable complexes with binding energies in ranges of −9.04 to −5.02 kcal mol⁻¹ (hERα receptor) and −8.84 to −5.97 kcal mol⁻¹ (PI3Kα receptor). The compounds exhibited appreciable drug likeness predicted using SwissADME.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The studies showed that the isolated compounds could be used for the development of anticancer therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13056511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ovarian Cancer Mortality Predictors in Public Oncology Centers, Addis Ababa, Ethiopia: A Case–Control Study","authors":"Abrham Tesfaye Habteyes,&nbsp;Jembere Tesfaye Deressa,&nbsp;Roza Teshome Kassa","doi":"10.1002/cnr2.70537","DOIUrl":"10.1002/cnr2.70537","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ovarian cancer remains the most lethal gynecologic cancer and has the worst prognosis among all female reproductive malignancies worldwide. In Ethiopia, ovarian cancer is the third most prevalent malignancy among women, following breast and cervical cancers. Despite extensive research on the topic, evidence regarding the determinants of mortality among ovarian cancer patients remains limited. Therefore, the primary aim of this study was to identify predictors of ovarian cancer mortality among patients receiving care at oncology centers in Addis Ababa, Ethiopia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A facility-based case–control study was conducted among women with ovarian cancer enrolled at oncology centers in Addis Ababa. A total of 137 cases and 274 controls were selected using the stratified sampling method. Data were extracted from patient records with a structured data extraction tool. The effect of each predictor variable on ovarian cancer mortality was estimated using binary logistic regression at the 5% level of significance and the final model's goodness of fit was tested with the likelihood ratio test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study included 411 ovarian cancer patients. Advanced FIGO stage (III&amp;IV) (AOR: 2.85, 95% CI: [1.27–6.39]), advanced age (≥ 60) (AOR: 8.71; 95% CI: [3.89–19.48]), and comorbidity (AOR: 3.24, 95% CI: [1.69–6.19]) were found to be independent predictors of mortality, whereas urban residency (AOR: 0.36; 95% CI: [0.19–0.66]) and nonepithelial histological type (AOR: 0.12, 95% CI: [0.03–0.53]) were found to be protective factors. Moreover, patients not receiving pain medication had lower odds of mortality (AOR: 0.39; 95% CI: [0.22–0.69]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Multivariable logistic regression analysis identified the following factors as significant predictors of mortality among ovarian cancer patients: advanced FIGO stage, comorbidities, advanced age, nonepithelial histology, pain medication, and urban residency. Therefore, early detection through timely clinical evaluation and diagnosis and treatment should be emphasized. Moreover, patients identified with significant predictors of mortality should receive targeted clinical attention and closer follow-up to improve survival outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Haplo-Hematopoietic Stem Cell Transplantation for Juvenile Myelomonocytic Leukemia in a Child With Underlying Thrombocytopenia-Absent Radius Syndrome: A Unique Case","authors":"Sondus Al Sharidah,&nbsp;Ahmed Elhussien,&nbsp;Walid I. A. Soliman,&nbsp;Nesma I. Ellithy","doi":"10.1002/cnr2.70523","DOIUrl":"10.1002/cnr2.70523","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Thrombocytopenia-absent radius (TAR) syndrome is a rare congenital disorder characterized by bilateral radial aplasia with preserved thumbs and early-onset thrombocytopenia. While hematologic and skeletal abnormalities define the condition, its association with hematologic malignancies is extremely rare, with only a few reported cases of leukemia. Juvenile myelomonocytic leukemia (JMML) is an uncommon pediatric myelodysplastic/myeloproliferative neoplasm frequently linked to RAS pathway mutations. To our knowledge, JMML has not previously been reported in association with TAR syndrome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We report the case of a male infant diagnosed with TAR syndrome based on clinical features and molecular confirmation of a homozygous <i>RBM8A</i> c.-21G&gt;A variant. The patient presented initially with persistent thrombocytopenia, skeletal deformities, and neonatal sepsis-like manifestations. At 2 years of age, he developed pancytopenia and progressive splenomegaly. Bone marrow evaluation and molecular testing confirmed JMML harboring a pathogenic <i>NF1</i> mutation. He underwent successful haploidentical hematopoietic stem cell transplantation (HSCT) from a sibling donor, following a conditioning regimen of melphalan, treosulfan, cyclophosphamide, and anti-thymocyte globulin. The patient achieved full donor chimerism and hematologic remission with stable engraftment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case represents, to our knowledge, one of the very few—if not the first—reported instances of successful HSCT for JMML in a patient with TAR syndrome. It underscores the importance of vigilant surveillance in TAR patients for potential malignant transformation and demonstrates the curative potential of HSCT in rare congenital-hematologic overlap syndromes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"9 4","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13045293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147590275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}